--
本页收录老挝专利「--」的公开登记要点,由 OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "NAUCHNO-TEKHNOLOGICHESKAYA FARMACEVTICHESKAYA FIRMA "POLYSAN" 于 2017-09-07 提交申请,当前状态为已注册。公开档案中可核验:申请号 P/654,DIP 编号 LAP654,主管局代码 LA,保护类型 Patent - PCT National Phase。时间线要点:公开/公告日 2025-02-21;授权日 2025-02-20;届满/失效参考日 2037-09-07。国际分类 / IPC 标注为 A61K 31/194、A61K 31/455、A61K 31/675、A61K 31/708、A61K 47/02、A61K 47/18、A61K 9/08。发明人 / 设计人包括 KOVALENKO, Alexey Leonidovich、PETROV, Andrey Yurievich。代理机构 / 代理人记载为 Tilleke & Gibbins Lao Co., Ltd。公开摘要提示:The invention relates to the chemical and pharmaceutical industry. A method for producing a stabilized pharmaceutical composition in the fo…。
This Laos Patent “METHOD FOR PRODUCING A STABILIZED PHARMACEUTICAL COMPOSITION IN THE FORM OF AN AQUEOUS SOLUTION” is a public DIP intellectual-property record, filed by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "NAUCHNO-TEKHNOLOGICHESKAYA FARMACEVTICHESKAYA FIRMA "POLYSAN" on 2017-09-07; current status: Registered. Identifiers include application No. P/654; DIP id LAP654; protection kind Patent - PCT National Phase. Key dates: publication 2025-02-21; grant 2025-02-20; expiry reference 2037-09-07. Classification: A61K 31/194、A61K 31/455、A61K 31/675、A61K 31/708、A61K 47/02、A61K 47/18、A61K 9/08. Inventor(s)/designer(s): KOVALENKO, Alexey Leonidovich, PETROV, Andrey Yurievich. Abstract hint: The invention relates to the chemical and pharmaceutical industry. A method for producing a stabilized pharmaceutical composition in the fo…. This prose is informational only and does not constitute legal advice, ownership proof or an infringement opinion.
ໜ້ານີ້ສະຫຼຸບ ສິດທິບັດ «--» ຈາກຂໍ້ມູນຈົດທະບຽນເປີດ, ຍື່ນໂດຍ OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "NAUCHNO-TEKHNOLOGICHESKAYA FARMACEVTICHESKAYA FIRMA "POLYSAN" ໃນວັນທີ 2017-09-07; ສະຖານະ ຈົດທະບຽນແລ້ວ. ຕົວລະບຸ: ເລກທີຄຳຮ້ອງ P/654; ລະຫັດ DIP LAP654; ປະເພດການປົກປ້ອງ Patent - PCT National Phase. ວັນທີສຳຄັນ: ວັນເຜີຍແຜ່ 2025-02-21; ວັນຈົດທະບຽນ/ອະນຸຍາດ 2025-02-20; ວັນໝົດອາຍຸ 2037-09-07. ປະເພດ/ຫ້ອງ: A61K 31/194、A61K 31/455、A61K 31/675、A61K 31/708、A61K 47/02、A61K 47/18、A61K 9/08. ນັກປະດິດ/ນັກອອກແບບ: KOVALENKO, Alexey Leonidovich, PETROV, Andrey Yurievich. ສະຫຼຸບ: The invention relates to chemical and pharmaceutical industry and, in particular, to a. ຂໍ້ມູນເພື່ອອ້າງອີງເທົ່ານັ້ນ ບໍ່ແມ່ນຄຳແນະນຳທາງກົດໝາຍ ຫຼື ໃບຢັ້ງຢືນສິດ.
P/654
图样
基础信息
- 类型
- 专利
- 申请号
P/654- 状态
- 已注册
- 申请人
- OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "NAUCHNO-TEKHNOLOGICHESKAYA FARMACEVTICHESKAYA FIRMA "POLYSAN"
- 代理机构
- Tilleke & Gibbins Lao Co., Ltd
- 申请日期
- 2017-09-07
- 注册号
P/654- 公开/公告日
- 2025-02-21
- 注册/授权日
- 2025-02-20
- 届满日
- 2037-09-07
- 国际分类
- A61K 31/194 · A61K 31/455 · A61K 31/675 · A61K 31/708 · A61K 47/02 · A61K 47/18 · A61K 9/08
- 商品 / 服务
- —
办理流程
根据当前状态动态标注-
提交申请
-
形式审查
-
实质审查
-
公开
-
授权
关联分析
LaoBiz 企业数据库联动类似专利推荐
摘要
The invention relates to chemical and pharmaceutical industry and, in particular, to a
method for producing a stabilized pharmaceutical composition presented as an aqueous solution
that may be used to obtain an intravenous drug containing succinic acid, nicotinamide, inosine and
riboflavin mononucleotide as the active ingredients and possessing cytoprotective properties.
The invention objective is to develop a method for producing the known stabilized
pharmaceutical composition presented as an aqueous solution that would enable to enhance its
safety in use through the application ofthermal sterilization. The objective is achieved by a method for producing a stabilized pharmaceutical
composition presented as an aqueous solution containing succinic acid, inosine, nicotinamide,
riboflavin mononucleotide sodium as the active ingredients, by way ofdissolving them in water
with subsequent sterile filtratioru wherein, in accordance with the invention, the composition is
supplemented by one or several ofthe pharmaceutically acceptable components as the stabilizing agent to be selected from the goup including sodium hydroxide,
tris(hydroxymethyl)aminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate,
meglumine, up to a stable solution with pH from 6.0 to 8.0, the components' ratio,Tow! being as
follows: succinic acid 5.00-12.50 inosine 1.00-2.40 nicotinamide 0.50- 1.20 riboflavin mononucleotide sodium 0.10-0.24 stabilizing agent 3.21-51.30 water up to 100.00lo, and the solution is subjected to additional thermal sterilization at l00oC with exposure time of8
minutes to I I 6'C with exposure time of 2 minutes.
In a particular embodiment, the objective is achieved by adding sodium hydrocarbonate to the composition as the stabilizing agent, up to a stable solution with pH of 6.0 to 7.0, the
components' ratio,Yowl. being as follows: succinic acid 5'00-12.50 inosine 1.00-2.40 nicotinamide 0.50-1.20 riboflavin mononucleotide sodium 0.10-0.24
The invention relates to the chemical and pharmaceutical industry. A method for producing a stabilized pharmaceutical composition in the form of an aqueous solution comprising active ingredients which include succinic acid, inosine, nicotinamide and riboflavin mononucleotide sodium salt, wherein a stabilizing agent is further introduced into the composition as one or more pharmaceutically acceptable ingredients selected from the group consisting of sodium hydroxide, tris-(oxymethyl)aminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate and meglumine to obtain a stable aqueous solution having a pH value in the range of 6.0 to 8.0; the method further comprises a sterilizing filtration of the resulting dissolved composition, and an additional thermal sterilization at temperatures from 100°C and an exposure time of 8 minutes to 116°C and an exposure time of 2 minutes.sodium hydrocarbonate 13.70-17.20 water uP to 100.0%.
Further in particular embodiment, the objective is achieved by additionally introducing
sodium hydrocarbonate to the composition as the stabilizing agent, up to a stable solution with pH
of 6.4 to 7.4, the components' ratio,Towt. being as follows: succinic acid 5.00-12.50 inosine I '00-2.40 nicotinamide 0.50-1.20 riboflavin mononucleotide sodium 0.10-0.24 sodium hydrocarbonate 13.70-17.20 water uP to 100.0%.